The Valley Desk

NCT02184572 · Interventional trial

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Overall registry status Completed

Phase 3

Conditions Measles-Mumps-Rubella Vaccine, Measles; Mumps; Rubella

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov